CORT:NSC-Corcept Therapeutics Incorporated (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 23.88

Change

+0.56 (+2.40)%

Market Cap

USD 1.00B

Volume

1.83M

Analyst Target

USD 15.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.15 (+0.72%)

USD 109.10B
REGN Regeneron Pharmaceuticals Inc

-10.23 (-1.05%)

USD 107.30B
MRNA Moderna Inc

+3.62 (+2.80%)

USD 44.96B
ARGX argenx NV ADR

-0.36 (-0.10%)

USD 22.43B
BNTX BioNTech SE

+0.78 (+0.85%)

USD 22.34B
ALNY Alnylam Pharmaceuticals Inc

+3.82 (+2.59%)

USD 18.64B
BGNE BeiGene Ltd

+6.15 (+3.73%)

USD 18.28B
GMAB Genmab AS

-0.57 (-1.89%)

USD 18.26B
BMRN Biomarin Pharmaceutical Inc

-3.43 (-4.27%)

USD 15.29B
TECH Bio-Techne Corp

-0.66 (-0.79%)

USD 13.26B

ETFs Containing CORT

FBT First Trust NYSE Arca Bio.. 3.72 % 0.57 %

+0.17 (+-0.25%)

USD 1.11B
FBT:LSE First Trust Global Funds .. 3.44 % 0.00 %

-4.00 (-0.25%)

USD 6.57M
FBTU:LSE First Trust Global Funds .. 3.44 % 0.00 %

-0.05 (-0.25%)

USD 6.57M
JSML Janus Henderson Small Cap.. 2.59 % 0.50 %

-0.42 (-0.25%)

USD 0.21B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.48% 28% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.48% 28% F 21% F
Trailing 12 Months  
Capital Gain 3.38% 66% D+ 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.38% 66% D+ 51% F
Trailing 5 Years  
Capital Gain 89.07% 84% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 89.07% 83% B 84% B
Average Annual (5 Year Horizon)  
Capital Gain 24.74% 76% C+ 83% B
Dividend Return 24.74% 76% C+ 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.65% 72% C 50% F
Risk Adjusted Return 67.52% 98% N/A 89% A-
Market Capitalization 1.00B 91% A- 83% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 234.80 24% 38%
Price/Book Ratio 4.82 30% 23%
Price / Cash Flow Ratio 18.64 3% 15%
Price/Free Cash Flow Ratio 18.90 2% 14%
Management Effectiveness  
Return on Equity 21.05% 98% 90%
Return on Invested Capital 17.62% 90% 87%
Return on Assets 11.13% 99% 96%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.